Boston Scientific Corporation logo
Boston Scientific Corporation (BSX)
Compare

Boston Scientific Corporation (BSX) Current Ratio: 1.62

Is Boston Scientific Corporation’s current ratio high or low?

Boston Scientific Corporation's current ratio of 1.62 is 10% above its 5-year average of 1.47, near the high end of its 5-year range (1.08–1.82).

As of Wednesday, June 17, 2026. 20.00% above its 12-month average of 1.35.

BSX Current Ratio Chart

BSX Current Ratio
1.62+50.00% 1Y
Zoom

BSX Average Current Ratio Chart

BSX Current vs Average Current Ratio Chart

BSX Current Ratio Metrics

CURRENT RATIO

1.62

CURRENT RATIO AVG TTM

1.35

CURRENT RATIO AVG 3Y

1.38

CURRENT RATIO AVG 5Y

1.47

CURRENT RATIO AVG 10Y

1.23

CURRENT RATIO AVG 15Y

1.35

CURRENT RATIO AVG 20Y

1.47

CURRENT VS TTM AVG

+20.00%

CURRENT VS 3Y AVG

+17.18%

CURRENT VS 5Y AVG

+10.08%

CURRENT VS 10Y AVG

+31.32%

CURRENT VS 15Y AVG

+19.78%

CURRENT VS 20Y AVG

+9.98%

BSX Competitors' Current Ratio

NAMEMARKET CAPCURRENT RATIOTTM3Y5Y
Boston Scientific Corporation (BSX)$69.74B1.621.351.381.47
Regeneron Pharmaceuticals, Inc. (REGN)vs ›$62.78B4.134.434.904.47
Cigna Corporation (CI)vs ›$77.02B0.850.840.800.80
Cencora, Inc. (COR)vs ›$54.76B0.900.890.890.92
Cardinal Health, Inc. (CAH)vs ›$53.55B0.940.961.001.04
Elevance Health Inc. (ELV)vs ›$86.74B1.241.171.081.07
Becton, Dickinson and Company (BDX)vs ›$52.72B1.111.141.161.25
HCA Healthcare, Inc. (HCA)vs ›$88.05B0.830.961.121.22
Humana Inc. (HUM)vs ›$45.03B0.720.580.570.58
IDEXX Laboratories, Inc. (IDXX)vs ›$44.83B1.171.241.231.33

Liquidity Analysis

Current Ratio

1.62

Quick Ratio

1.08

Boston Scientific Corporation Current Ratio Formula & Definition

Current Ratio = Current Assets / Current Liabilities

The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Boston Scientific Corporation Current Ratio FAQ

What is the current ratio for Boston Scientific Corporation (BSX)?
The current ratio for BSX stock is 1.62.
Is Boston Scientific Corporation's current ratio high or low?
Boston Scientific Corporation's current ratio of 1.62 is 10% above its 5-year average of 1.47, near the high end of its 5-year range (1.08–1.82).
What is the TTM average current ratio for Boston Scientific Corporation (BSX)?
The TTM average current ratio for BSX stock is 1.35.
What is the 3Y average current ratio for Boston Scientific Corporation (BSX)?
The 3Y average current ratio for BSX stock is 1.38.
What is the 5Y average current ratio for Boston Scientific Corporation (BSX)?
The 5Y average current ratio for BSX stock is 1.47.
What is the 10Y average current ratio for Boston Scientific Corporation (BSX)?
The 10Y average current ratio for BSX stock is 1.23.
What is the 15Y average current ratio for Boston Scientific Corporation (BSX)?
The 15Y average current ratio for BSX stock is 1.35.
What is the 20Y average current ratio for Boston Scientific Corporation (BSX)?
The 20Y average current ratio for BSX stock is 1.47.

Boston Scientific Corporation Current Ratio History

DATECURRENT RATIO
2025-12-311.62
2024-12-311.08
2023-12-311.32
2022-12-311.51
2021-12-311.48
2020-12-311.82
2019-12-310.97
2018-12-310.76
2017-12-310.68
2016-12-310.90
2015-12-311.43
2014-12-311.51
2013-12-311.74
2012-12-311.71
2011-12-311.72
2010-12-311.39
2009-12-311.34
2008-12-311.70
2007-12-311.82
2006-12-311.86
2005-12-311.78
2004-12-311.26
2003-12-311.35
2002-12-311.31
2001-12-311.33
2000-12-311.21
1999-12-311.00
1998-12-310.78
1997-12-311.32
1996-12-311.61

About Boston Scientific Corporation

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA
53,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Michael F. Mahoney